$3.10
0.00%
Nasdaq, Fri, Sep 20 2024
ISIN
US29604W1080
Symbol
ERYP
Sector
Industry

ERYTech Pharma SA Sponsored ADR Stock price

$3.10
+0.00 0.00% 1M
+0.00 0.00% 6M
-1.34 30.18% YTD
-1.97 38.86% 1Y
-60.80 95.15% 3Y
-49.73 94.13% 5Y
-240.90 98.73% 10Y
Nasdaq, Closing price Fri, Sep 20 2024
+0.00 0.00%
ISIN
US29604W1080
Symbol
ERYP
Sector
Industry

Key metrics

Market capitalization $30.94m
Enterprise Value $34.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.72
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-27.01m
Free Cash Flow (TTM) Free Cash Flow $-26.59m
EPS (TTM) EPS $-38.96
P/E forward negative
Short interest 0.08%
Show more

Is ERYTech Pharma SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

ERYTech Pharma SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a ERYTech Pharma SA Sponsored ADR forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a ERYTech Pharma SA Sponsored ADR forecast:

Buy
100%

Financial data from ERYTech Pharma SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
- -
-
100%
- Direct Costs 0.79 0.79
88% 88%
-
-0.79 -0.79
88% 88%
-
- Selling and Administrative Expenses 14 14
89% 89%
-
- Research and Development Expense 11 11
30% 30%
-
-26 -26
12% 12%
-
- Depreciation and Amortization 0.79 0.79
88% 88%
-
EBIT (Operating Income) EBIT -27 -27
25% 25%
-
Net Profit -25 -25
8,090% 8,090%
-

In millions USD.

Don't miss a Thing! We will send you all news about ERYTech Pharma SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ERYTech Pharma SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
about one year ago
Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023.
Neutral
Seeking Alpha
more than one year ago
Erytech Pharma SA (NASDAQ:ERYP ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Gil Beyen - CEO Thibaut du Fayet - CEO, Pherecydes Pharma Didier Hoch - Chairman, Pherecydes Pharma Conference Call Participants Jacob Mekhael - Kempen & Co. Operator Thank you for standing by, and welcome to the conference call on the proposed merger between ERYTECH Pharma and Pherecy...
Neutral
Seeking Alpha
almost 2 years ago
ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q3 2022 Earnings Conference Call November 22, 2022 8:30 AM ET Company Participants Gil Beyen - CEO Eric Soyer - CFO and COO Conference Call Participants Boris Peaker - Cowen Operator Good morning, and thank you for standing by.

Company Profile

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Head office France
CEO Thibaut Fayet
Employees 68
Founded 2004
Website www.phaxiam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today